Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. (Upsher-Smith) presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy™ XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). In a separate presentation, researchers also reported that when Qudexy™ XR capsules were opened and sprinkled onto soft food, they remained bioequivalent to intact capsules, making them a useful alternative for patients with swallowing difficulties. These results were presented at the American Academy of Neurology's (AAN) Annual Meeting in Washington, DC on April 18-25, 2015. Qudexy™ XR, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile, is an extended-release formulation of topiramate studied in a Phase 3, randomized, double-blind, placebo-controlled trial (PREVAIL) and the only extended-release topiramate formulation to have been approved by the Food and Drug Administration (FDA) for administration via the sprinkle method.

The PREVAIL OLE study of Qudexy™ XR enrolled 96.8% of participants who completed the original Phase 3 PREVAIL trial and had a completion rate of 70%. New individual neurocognitive / neuropsychiatric treatment-emergent adverse events (TEAEs) were reported in <3% of patients, with the exception of aphasia (5.2%) and depression (3.8%).

Data from a study evaluating an alternative administration method for Qudexy™ XR was also presented. In a Phase 1, randomized, single-dose crossover study (n=36) of Qudexy™ XR, researchers compared pharmacokinetic parameters when Qudexy™ XR was administered as an intact capsule to those when the capsule was opened and the beads were sprinkled onto soft food. AUC and Cmax were bioequivalent between Qudexy™ XR beads sprinkled onto soft food and the intact capsule (90% CI: AUC0-∞ 0.98-1.05; Cmax 1.03-1.14). Median Tmax was between 10-14 hours. In separate in vitro experiments, Qudexy™ XR beads were successfully passed through >/= 14 French G-/J-tubes.

"We are pleased that favorable data continues to emerge from the comprehensive clinical trials of Qudexy™ XR," said Steve Chung, M.D., Professor of Neurology at Banner University Medical Center, Phoenix and trial investigator. "The Phase 3 PREVAIL trial demonstrated that Qudexy™ XR met its primary and secondary endpoints for efficacy, and the open-label extension study supports the favorable safety profile and long-term use of Qudexy™ XR. This scientific data, combined with its dosing flexibility, substantiates the use of Qudexy™ XR as a potential treatment option for patients with seizure disorders."

Source:

Upsher-Smith Laboratories, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A randomized trial of mexiletine and lamotrigine in adults with non-dystrophic myotonia